Successful remission induction therapy with gilteritinib in a patient with de novo FLT3‐mutated acute myeloid leukaemia and severe COVID‐19

Wilson, Andrew J.; Troy‐Barnes, Ethan; Subhan, Maryam; Clark, Fiona; Gupta, Rajeev; Fielding, Adele K.; Kottaridis, Panagiotis; Mansour, Marc R; O’Nions, Jenny; Payne, Elspeth; Chavda, Naina; Baker, Robert; Thomson, Kirsty; Khwaja, Asim

The optimal treatment for patients with newly diagnosed acute myeloid leukaemia (AML) who are infected with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)/COVID‐19 is unknown.(1) We report the case of a previously fit 27‐year‐old male who presented with a 3‐day history of fever (>39 C), swollen, erythematous elbows and no respiratory symptoms. His white blood count (WBC) was 187×10(9)/L and bone marrow (Figure 1A & 1C) examination revealed normal karyotype AML with a fms related receptor tyrosine kinase 3 (FLT3) internal tandem duplication (ITD), wild‐type NPM1 and no additional mutations on a next‐generation sequencing panel.